医学
生活质量(医疗保健)
全身疗法
临床试验
重症监护医学
肝细胞癌
肿瘤科
内科学
结直肠癌
不利影响
癌症
乳腺癌
护理部
作者
Léa Muzellec,Héloïse Bourien,Julien Edeline
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2021-12-30
卷期号:14 (1): 179-179
被引量:12
标识
DOI:10.3390/cancers14010179
摘要
Quality of life (QoL) in oncology is an outcome becoming more and more important and relevant to explore. Some studies have demonstrated its prognostic impact in different cancers, such as colorectal, breast, and prostate cancers, but also in hepatocellular carcinoma (HCC). Different tools have been developed for assessing quality of life, some general, such as EORTC QLQ-C30, but also specific tools depending on cancer origin which seem to be more pertinent for patients. Systemic treatments and specific symptoms due to cancer evolution could decrease quality of life. For approval of new systemic treatments, authorities ask for benefit in terms of efficacy but also benefit in quality of life, which is crucial for patients. This review reports data about QoL in HCC, including specific tools used, impact of systemic treatments and prognosis for QoL for HCC patients. Management of adverse events is essential to enhance compliance with treatment and quality of life. Assessing quality of life in clinical trials appears quite systematic, but its application in clinical routine requires development.
科研通智能强力驱动
Strongly Powered by AbleSci AI